<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85103655840</prism:url><dc:identifier>SCOPUS_ID:85103655840</dc:identifier><eid>2-s2.0-85103655840</eid><pubmed-id>33774115</pubmed-id><pii>S0169409X21000855</pii><prism:doi>10.1016/j.addr.2021.03.011</prism:doi><dc:title>Oral delivery of peptide therapeutics in infants: Challenges and opportunities</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><citedby-count>2</citedby-count><prism:publicationName>Advanced Drug Delivery Reviews</prism:publicationName><dc:publisher>Elsevier B.V.</dc:publisher><source-id>19409</source-id><prism:issn>18728294 0169409X</prism:issn><prism:volume>173</prism:volume><prism:startingPage>112</prism:startingPage><prism:endingPage>124</prism:endingPage><prism:pageRange>112-124</prism:pageRange><prism:coverDate>2021-06-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="56406953800"><ce:initials>J.P.</ce:initials><ce:indexed-name>Gleeson J.P.</ce:indexed-name><ce:surname>Gleeson</ce:surname><ce:given-name>John P.</ce:given-name><preferred-name><ce:initials>J.P.</ce:initials><ce:indexed-name>Gleeson J.P.</ce:indexed-name><ce:surname>Gleeson</ce:surname><ce:given-name>John P.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56406953800</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>Â© 2021 The Author(s)</publishercopyright><ce:para>The vast majority of drugs are not designed or developed for pediatric and infant populations. Peptide drugs, which have become increasingly relevant in the past several decades, are no exception. Unfortunately, nearly all of the 60+ approved peptide drugs are formulated for injection, a particularly unfriendly mode of administration for infants. Although three peptide drugs were recently approved for oral formulations, this major advance in peptide drug delivery is available only for adults. In this review, we consider the current challenges and opportunities for the oral formulation of peptide therapeutics, specifically for infant populations. We describe the strategies that enable oral protein delivery and the potential impact of infant physiology on those strategies. We also detail the limited but encouraging progress towards 1) adapting conventional drug development and delivery approaches to infants and 2) designing novel infant-centric formulations. Together, these efforts underscore the feasibility of oral peptide delivery in infants and provide motivation to increase attention paid to this underserved area of drug delivery and formulation.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85103655840" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85103655840&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85103655840&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"><affilname>Carnegie Mellon University</affilname><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><authors><author seq="1" auid="56406953800"><ce:initials>J.P.</ce:initials><ce:indexed-name>Gleeson J.P.</ce:indexed-name><ce:surname>Gleeson</ce:surname><ce:given-name>John P.</ce:given-name><preferred-name><ce:initials>J.P.</ce:initials><ce:indexed-name>Gleeson J.P.</ce:indexed-name><ce:surname>Gleeson</ce:surname><ce:given-name>John P.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56406953800</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="2" auid="57193827742"><ce:initials>K.C.</ce:initials><ce:indexed-name>Fein K.C.</ce:indexed-name><ce:surname>Fein</ce:surname><ce:given-name>Katherine C.</ce:given-name><preferred-name><ce:initials>K.C.</ce:initials><ce:indexed-name>Fein K.C.</ce:indexed-name><ce:surname>Fein</ce:surname><ce:given-name>Katherine C.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57193827742</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="3" auid="35609935600"><ce:initials>K.A.</ce:initials><ce:indexed-name>Whitehead K.A.</ce:indexed-name><ce:surname>Whitehead</ce:surname><ce:given-name>Kathryn A.</ce:given-name><preferred-name><ce:initials>K.A.</ce:initials><ce:indexed-name>Whitehead K.A.</ce:indexed-name><ce:surname>Whitehead</ce:surname><ce:given-name>Kathryn A.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35609935600</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></authors></abstracts-retrieval-response>